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Introduction: An unwanted consequence of population aging is the growing number
of elderly at risk of neurodegenerative disorders, including dementia and macular
degeneration. As nutritional and behavioral changes can delay disease progression, we
designed the Walnuts and Healthy Aging (WAHA) study, a two-center, randomized, 2-
year clinical trial conducted in free-living, cognitively healthy elderly men and women. Our
interest in exploring the role of walnuts in maintaining cognitive and retinal health is based
on extensive evidence supporting their cardio-protective and vascular health effects,
which are linked to bioactive components, such as n-3 fatty acids and polyphenols.
Methods: The primary aim of WAHA is to examine the effects of ingesting walnuts
daily for 2 years on cognitive function and retinal health, assessed with a battery
of neuropsychological tests and optical coherence tomography, respectively. All
participants followed their habitual diet, adding walnuts at 15% of energy (≈30–
60 g/day) (walnut group) or abstaining from walnuts (control group). Secondary
outcomes include changes in adiposity, blood pressure, and serum and urinary
biomarkers in all participants and brain magnetic resonance imaging in a subset.
Results: From May 2012 to May 2014, 708 participants (mean age 69 years, 68%
women) were randomized. The study ended in May 2016 with a 90% retention rate.
Discussion: The results of WAHA might provide high-level evidence of the benefit of
regular walnut consumption in delaying the onset of age-related cognitive impairment
and retinal pathology. The findings should translate into public health policy and sound
recommendations to the general population (ClinicalTrials.gov identifier NCT01634841).
Keywords: cognitive decline, Alzheimer’s disease, age-related macular degeneration, dietary intervention,
walnuts, randomized trial, aging
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INTRODUCTION
The worldwide expansion of aging populations has become
a major public health challenge (Song and Chen, 2015).
Increased lifespan has resulted in a steady rise of debilitating
diseases related to aging, including neurodegenerative disorders,
such as Alzheimer’s disease (AD), the most common type
of dementia (Alzheimer’s Association, 2015), and age-related
macular degeneration (AMD), the leading cause of visual loss
and blindness worldwide (Lim et al., 2012). Unfortunately, to date
there is no effective treatment for AD (Iqbal et al., 2014) or even
mild cognitive impairment (MCI), its precursor stage (Cooper
et al., 2013). Likewise, no effective preventive strategies exist
for AMD, although nutritional and behavioral modifications can
delay disease progression once initiated (Lim et al., 2012). In the
continuum from normal cognition to MCI and dementia there is
age-related cognitive decline, the onset and progression of which
depends on a number of factors, including genetic variation,
the level of education, environmental factors, particularly dietary
habits, and the presence of cardiovascular risk factors or disease
(Baumgart et al., 2015). Similar risk factors, albeit with a different
genetic background, play a role in the pathophysiology of AMD
(Lim et al., 2012). Optimal cognitive and visual functions are
essential for quality of life and developing effective primary
prevention strategies to reduce the economic and societal burden
of such common age-related diseases would be of utmost public
health importance.
Oxidative stress and inflammation are thought to play
a pivotal role in precipitating neurodegenerative diseases,
including AD (Schrag et al., 2013; Heneka et al., 2015) and
AMD (Khandhadia and Lotery, 2010). Consequently, as derived
from epidemiologic studies, a promising hypothesis in recent
years has been that antioxidant-rich foods, such as fruit,
vegetables, and particularly seeds and berries (Nooyens et al.,
2011; Valls-Pedret et al., 2012; Ros and Hu, 2013; Barbour
et al., 2014; O’Brien et al., 2014), and plant-based dietary
patterns, especially the Mediterranean diet and the DASH
(Dietary Approaches to Stop Hypertension) dietary pattern
(Otaegui-Arrazola et al., 2014; Tangney et al., 2014) may
protect from cognitive decline and AD. Nutrients such as n-
3 polyunsaturated fatty acids (n-3 PUFA) and antioxidants,
namely polyphenols, carotenoids and vitamins C and E, may
have a role in preventing both cognitive impairment (Macready
et al., 2009; Dangour et al., 2012; Valls-Pedret et al., 2012;
Devore et al., 2013; Barnes et al., 2014; Otaegui-Arrazola
et al., 2014) and macular degeneration (Age-Related Eye Disease
Study Research Group, 2001; Parisi et al., 2008; Tan et al.,
2009; Majumdar and Srirangam, 2010; Merle et al., 2013).
Nuts in general and walnuts in particular have a rich matrix
of these bioactive components and through additive effects
have the potential to beneficially impact neuronal function in
the brain and the retina (Poulose et al., 2014). Prospective
studies have provided support for the association between
nut consumption and improved cognitive performance (Valls-
Pedret et al., 2012; O’Brien et al., 2014) and lower incidence
of AMD (Tan et al., 2009; Amirul Islam et al., 2014). Among
the different tree nuts, walnuts contain n-3 PUFA, specifically
α-linolenic acid (ALA; C18:3n-3). ALA has long been believed
to improve brain health indirectly via modest conversion to
docosahexaenoic acid (DHA; C22:6n-3) (Domenichiello et al.,
2015), which has been found to modulate brain plasticity and
counteract neuroinflammation in experimental studies (Dyall,
2015). However, studies in rodents uncovered brain benefits of
ALA by itself, including increased brain plasticity (Blondeau
et al., 2009), reduced cell death and calcium dysregulation
(Carey et al., 2013), and reduced amyloid-beta deposition (Gao
et al., 2016). Other bioactive compounds in walnuts, such
as arginine, tocopherols, folate, melatonin, and polyphenols
also support neurological health and cognitive wellness by
modulating blood pressure, HDL function, glucoregulation,
endothelial vasodilator function, arterial compliance, oxidative
status, and vascular inflammation (Carey et al., 2013; Del Rio
et al., 2013; O’Brien et al., 2014). In support, experimental
feeding studies in aged rodents have shown that walnuts improve
age-related motor and cognitive deficits as assessed by rod
walk, plank walk, and Morris water maze tests (Willis et al.,
2009).
Easy to implement lifestyle modifications that might help
prevent chronic non-communicable disorders need to be
uncovered, with the concept that even small changes in the right
direction can lead to substantial benefit for global health. Thus,
delaying the onset of AD by only 5 years would significantly
reduce its prevalence by the next decade (OECD, 2014). Thus far
randomized controlled trials (RCTs) testing various interventions
in patients with established AD have failed to show any benefit,
probably because at this stage neuropathology is far advanced
and irreversible. This underlines the need to conduct RCTs in
individuals at risk but cognitively healthy, when there are little
or no underlying brain changes.
Although not primarily focused on neurodegenerative
disorders, one such study, the PREvención con DIeta MED-
iterránea (PREDIMED) study, is a landmark RCT conducted
in older individuals at high cardiovascular risk that has shown
beneficial effects of Mediterranean diets supplemented with
extra-virgin olive oil or mixed nuts on several age-related
disorders after intervention for ∼5 years (Martínez-González
et al., 2015). In the PREDIMED trial, the Mediterranean diets
reduced the incidence of cardiovascular diseases by 30%,
compared with a low-fat control diet, while the risk of stroke was
reduced by 34% by the olive oil diet and by 49% by the nuts diet
(Estruch et al., 2013). In a PREDIMED sub-study, we showed
better cognitive performance associated with consumption of
polyphenol-rich Mediterranean foods at baseline (Valls-Pedret
et al., 2012) and cognitive improvement in participants allocated
the two Mediterranean diets compared with those in the control
group after 4.1 years of follow-up (Valls-Pedret et al., 2015). Thus,
data from PREDIMED suggest that nuts, including walnuts, are
a good option for cardiovascular and brain health. Therefore, it
is reasonable to surmise that usual walnut consumption may be
an effective approach to preserve cognitive abilities and visual
function. However, while there is sufficient rationale for the
role of walnuts in neuroprotection, direct clinical evidence is
lacking. The Walnuts and Healthy Aging (WAHA) study is
the first RCT assessing cognitive function and macular health
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in an elderly cohort following daily ingestion of walnuts for
2 years.
METHODS
Study Design
The WAHA study is a dual center, single blind, randomized
2-year clinical trial conducted in free living, cognitively
healthy elderly individuals1. The study is carried out in
two centers: Loma Linda University, CA, USA (LLU) and
Hospital Clínic, Barcelona, Spain (BCN). With a parallel design,
participants were randomized to either the walnut group
(consuming walnuts daily) or control group (abstaining from
walnuts). Otherwise participants followed their habitual diet
throughout the study. Primary aims are to assess changes in
cognitive function and retinal integrity. Secondary aims relate
to effects on cardio-metabolic risk factors, body weight and
composition, and circulating markers of oxidation/inflammation.
Additional secondary aims (BCN center) are changes in brain
magnetic resonance imaging (MRI), ultrasound-assessed carotid
atherosclerosis, blood pressure by 24-h ambulatory monitoring,
bone mineral density, leukocyte telomere length, and microRNAs
(miRNAs) related to lipoprotein metabolism.
Participants and Eligibility Criteria
Recruitment and selection of participants took place between
May 2012 and May 2014; the trial ended May 31, 2016.
Participants were healthy elderly men and women with normal
cognitive and visual function at the time of recruitment. Inclusion
criteria were age between 63 and 79 years, apparently healthy,
and equally willing to be in either of the two groups. Exclusion
criteria included inability to undergo neuropsychological testing;
morbid obesity (BMI ≥ 40 kg/m2); uncontrolled diabetes
(HbA1c > 8%); uncontrolled hypertension (on-treatment blood
pressure ≥ 150/100 mmHg); prior stroke, significant head
trauma or brain surgery; relevant psychiatric illness; major
depression; cognitive deterioration or dementia with a score
< 24 on the Mini-Mental State Examination (MMSE) (Folstein
et al., 1975); other neurodegenerative disorders like Parkinson’s
disease; advanced AMD or eye-related conditions precluding
ophthalmological evaluation; prior chemotherapy; chronic illness
with projected shortened lifespan; allergy to walnuts; customary
use of fish oil and/or tree nuts (> 2 servings/week) and/or
other relevant sources of ALA, such as flaxseed oil or soy
lecithin.
Eligible participants were recruited via mailing study
brochures (LLU) or through the non-profit organization Institute
of Aging (BCN), advertisements in the study centers, and word of
mouth. Interested individuals attended an informational group
meeting, completed a short medical questionnaire and signed the
informed consent. Next candidates had a face-to-face interview
with the study clinician, who assessed potential compliance,
reviewed the medical history, inclusion and exclusion criteria,
and recent blood work and use of medications or supplements,
1https://clinicaltrials.gov/show/NCT01634841
and administered the MMSE. Eligible participants were
scheduled to have baseline tests (neuropsychological and
ophthalmologic evaluations and collection of fasting blood
and urine) and were then randomized to either the control or
walnut group using a computerized random number table with
stratification by center, sex, and age range. Couples entering the
study were treated as one number and were randomized into the
same group.
Intervention
Participants received 15% of daily energy intake as walnuts for
2 years or abstained from walnuts. To estimate the required
amount of walnuts, participants completed a 3-day diet history
and a physical activity questionnaire at baseline. The physical
activity factor and the energy requirements were obtained using
the World Health Organization formula for energy needs for
adults > 60 years (World Health Organization, 1985). The
estimated amount of walnuts ranged from 1 to 2 oz/day (≈30–
60 g/day). Sachets for daily consumption containing 30, 45, or
60 g of raw, pieced walnuts were provided as 8-week allotments
to the participants in the walnut group at the time of their 2-
monthly clinic visits with the dietitians. Instructions were given
to eat walnuts daily, preferably as the raw product, either as a
snack or by incorporating them into shakes, yogurts, cereals, or
salads. To improve participants’ compliance, 1-kg extra walnut
allowances were provided every 2 months to take into account
family needs. Participants in the control group were advised to
abstain from eating walnuts for the duration of the study. Use of
ALA-rich canola and soybean oils was restricted.
Once randomized, participants were scheduled for 2-month
visits with the study dietitians aimed at assessing compliance,
increasing retention, and collecting data on diet adherence,
medication changes, anthropometry, and clinical blood pressure.
For the walnut group participants, the dietitians noted any
side effects and collected used walnut sachets as a measure
of compliance. The rapport built by the dietitians with the
participant during the periodic scheduled visits was critical to
retain them for the entire length of study. Since participants in the
control group had no active intervention, to improve retention,
quarterly educational group activities unrelated to the study were
offered to them.
Outcomes
Primary outcomes are changes from baseline in the composite
score of all neuropsychological tests for cognition and in the
average thickness of the retinal nerve fiber layer of each eye, as
assessed by optical coherence tomography (OCT). As secondary
cognitive outcomes, we will analyze composites for different
cognitive domains, including memory, language, perception,
and frontal functions (for further detail, please see section
Cognitive Testing); assess the incidence of AD according to
NINCDS-ADRDA criteria (McKhann et al., 1984); and evaluate
the incidence of MCI, defined by Petersen’s diagnostic criteria
(Petersen et al., 2001). Secondary OCT outcomes are macula cube
thickness, cube volume, and central thickness.
Other secondary outcomes for the whole cohort are changes
in anthropometric measures, lipid profile, serum inflammatory
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and oxidative stress markers, red blood cell (RBC) fatty acids,
and urinary polyphenols. At the BCN site, the following
secondary outcomes will be assessed: structural and functional
brain MRI variables, carotid intima-media thickness (IMT) and
plaque burden, body composition, bone mineral density, 24-h
ambulatory blood pressure, leukocyte telomere length, and serum
miRNAs.
Measurements
Table 1 shows the variables measured in the WAHA trial and how
often they were measured.
Measurements at Both Sites
Dietary assessment
In BCN, a food frequency questionnaire (FFQ) including 44 food
groups was administered to all participants at baseline and end
of year 2. In LLU, after the 1st study year, participants filled in a
FFQ validated in a pilot sample of elderly persons (Segovia-Siapco
et al., 2007). During the study, dietary intake was monitored
by conducting five unannounced 24-h diet recalls over 2 years
(LLU) or 3-day food records every 6 months (BCN). Participants
allocated to the walnut diet who had difficulty chewing due
to dental problems were given a coffee grinder at no cost,
with instructions on how to consume the ground walnuts by
incorporating them to semifluid foods such as yogurt.
Clinical evaluation
A clinician saw the participants at baseline, when a general
questionnaire was filled in, and at the end of the study, when a
follow-up questionnaire was administered to assess final changes
in clinical status and medication and adverse events. In the
same visit clinical blood pressure was measured following the
recommendations of the European Societies of Hypertension and
Cardiology (ESH/ESC) (Mancia et al., 2013): after a 5-min rest
with the patient seated in a quiet environment, three measures of
BP were taken at 2-min intervals with a validated semiautomatic
oscillometer (Omron 705-CP, Omron Healthcare Group, Kyoto,
Japan). The mean of the last two measurements of systolic and
diastolic blood pressure was recorded as office blood pressure. An
electrocardiogram (ECG) was performed at baseline and end of
study.
Physical activity, anthropometry, and body composition
Physical activity was evaluated at baseline, year 1, and the end
of the study with a validated short version of the Minnesota
questionnaire (Elosua et al., 1994). The dietitians measured
height at baseline and 2 years using a wall mounted stadiometer,
body weight at baseline and every 2 months by calibrated scales,
and waist and hip circumferences every 6 months by using
an anthropometric tape midway between the lowest rib and at
the iliac crest and at the widest point in the hips, respectively.
Body composition was assessed at baseline and 2 years by
bioelectric impedance using a body composition analyzer (Tanita,
Model TBF-300A, Arlington Heights, IL, USA) at LLU and
by dual energy X-ray absorptiometry (DEXA) (Whole body
scanner GE-Lunar IDXA, GE Healthcare, Madison, WI, USA)
at BCN.
Cognitive testing
A comprehensive neuropsychological test battery evaluating
several cognitive domains was administered at baseline and at
the end of the trial. Neuropsychologists who were masked to
participant’s group assignment conducted the cognitive tests.
The instruments used were Block design from the Wechsler
Adult Intelligence Scale (WAIS III) (Wechsler, 1997), Rey-
Osterrieth Complex Figure (ROCF) (Rey, 1941), Rey Auditory
Verbal Learning Test (RAVLT) (Rey, 1958), Boston Naming Test
(Kaplan et al., 2001), Semantic category evocation of animals
(Ramier and Hécaen, 1970), Number location and incomplete
letters from the Visual Object and Space Perception Battery
(VOSP) (Warrington and James, 1991), Trail Making Test, parts
A and B (Partington and Leiter, 1949), Phonemic fluency (FAS)
(Benton and Hamsher, 1976), Stroop Color Word Test (Stroop,
1935), Symbol Digit Modalities Test (SDMT) (Smith, 1973),
Digit span forward and backward from the WAIS III (Wechsler,
1997), and the Conners Continuous Performance Test (CPT II)
(Conners and Staff, 2000).
Subjects’ raw test punctuations were standardized to z scores
to generate a global cognition composite by computing the
mean standardized changes of all neuropsychological tests. This
composite was pre-specified as the primary outcome of the
study. Moreover, composites of cognitive domains analyzed
separately were calculated. First, the memory composite included
the mean standardized individual change scores of the RAVLT
(immediate and delayed recall) and the 3-min recall of ROCF.
Language composite included scores from animal semantic
fluency and the Boston Naming Test. Perception composite
included scores from number location and incomplete letters
from VOSP battery and block design from WAIS-III battery.
Finally, a composite score related to frontal functions was
created including scores from TMT parts A and B, FAS, Stroop,
SDMT, digit span from WAIS-III, and CPT-II. As secondary
outcomes, composites assessing cognitive domains separately
were defined.
In addition, information about cognitive reserve and mood
was collected using a cognitive reserve questionnaire (Solé-
Padullés et al., 2009) and the Hamilton Depression Rating
Scale (Hamilton, 1967), respectively. Premorbid intelligence was
assessed with the American National Adult Reading Test (Grober
and Sliwinski, 1991) at LLU site and the Word Accentuation Test
(Del Ser et al., 1997) at BCN site.
Ophthalmologic evaluation
Retinal examinations were performed at baseline and end of
the study by ophthalmologists (BCN) and trained technicians
under the supervision of an ophthalmologist (LLU). The central
and average thickness and volume of the macular neurosensorial
retina and the thickness of the retinal nerve fiber layer were
ascertained by OCT (Cirrus HD OCT, Zeiss, Germany).
Biochemical measurements
Fasting blood samples and morning spot urine samples were
collected at baseline and end of years 1 and 2, and aliquots
of EDTA plasma, serum, buffy coat for DNA recovery, whole
blood, and urine samples are kept frozen at −80◦C. Participants
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TABLE 1 | Measurements in the Walnuts and Healthy Aging (WAHA) study.
Measurements Content Baseline Year 1 Year 2
Eligibility questionnaire Sex, age, inclusion, and exclusion criteria X
General/quality of life questionnaire∗ Marital and socioeconomic status, medical conditions,
medication
X X
Follow-up questionnaire, including withdrawal Symptoms and conditions, tolerance, medication
changes
X X
Food frequency questionnaire (FFQ)† Multiple food groups and foods X X
Diet recalls‡ All daily foods and beverages X X X
Physical activity questionnaire Short-version of the Minnesota questionnaire X X X
Clinical blood pressure X X X
Electrocardiogram¶ X X
Anthropometric measurements Height, body weight, waist, and hip circumferences, %
body fat§
X X X
Neuropsychological evaluation A complete test battery to assess cognitive function X X
Ophthalmological examination Optic nerve and macular optical coherence tomography X X
Standard blood chemistry Lipid profile, glucose, insulin, renal function, liver
function, blood count, others
X X X
Serum inflammatory and oxidative stress markers CRP, E-selectin, others X X
Urine chemistry Albumin, total polyphenols, ellagitannin, urolithins,
others
X X X
Red blood cell fatty acids Measure of compliance, performed in 30% of the cohort X X X
Genomic studies APOE, others X
Brain MRI¶ Performed in a subset (n = 120) X X
B-mode ultrasonography of carotid arteries¶ Carotid intima-media thickness and plaque burden X X
DEXA§ Body composition and bone mineral density X X
Twenty-four-hour ambulatory blood pressure
monitoring¶
Performed in 80% of the cohort X X
Leukocyte telomere length¶ Performed in all participants at baseline and only in
those with brain MRI at 1 and 2 years
X X X
Serum miRNAs¶ miRNAs involved in lipoprotein metabolism X X
BCN, Barcelona; LLU, Loma Linda University; CRP, C-reactive protein; MRI, magnetic resonance imaging; DEXA, dual-energy X-ray absorptiometry; miRNAs, microRNAs.
∗The general questionnaire was collected at baseline at both sites. At LLU this questionnaire was called the Quality of Life questionnaire and was collected at end of year
2 also and included more questions about the subjects’ mental health and well-being.
†Forty-four-food groups and items FFQ at baseline and year 2 at BCN; 150-food group and items FFQ once during the 2nd year at LLU.
‡Three-day (including one weekend day) self-recorded recalls in BCN at baseline, years 1 and 2; five unannounced 24-h recalls by telephone at LLU over 2 years.
§ Percent body fat measured by bioelectric impedance at LLU and by DEXA in BCN.
¶ Determined only at the BCN center.
reported on the assigned days after fasting for a minimum of
12 h. An experienced phlebotomist drew blood and samples
were centrifuged and aliquoted for the various assays and stored
immediately at −80◦C. All assays except routine chemistry for
safety assessment and determination of the APOE genotype were
performed at the end of the study to control for between-assay
variability. Extra aliquots were stored for additional outcomes
of interest to the investigators that might arise during or after
the completion of the study. Samples were shipped overnight
on dry ice to the appropriate laboratories for biochemical
determinations once the study was completed. Plasma and/or
serum samples will be used to determine changes in lipid
profile, glycemic control, liver and renal function tests, and
inflammation and oxidation biomarkers. Extra aliquots of all
samples have been stored at −80◦C. To reduce assay variability,
all samples for a specific assay will be run together in the same
laboratory.
An objective biological marker of compliance with walnut
consumption, the RBC fatty acid proportions of ALA (Sala-Vila
et al., 2011), was assessed in a randomly selected subset (30% of
participants) at baseline and years 1 and 2. Given that walnuts
have one of the highest polyphenol content of all edible plants
(Carey et al., 2013), the urinary content of total polyphenols
(Valls-Pedret et al., 2012) will also be used as an indirect marker
of compliance.
Genetic testing
The APOE genotype will be determined by using the method of
Hixson and Vernier (Hixson and Vernier, 1990).
Measurements Only at BCN Site
Some techniques were performed only at the BCN center based
on prior expertise, availability, and cost.
Brain magnetic resonance imaging
Approximately 120 participants underwent brain MRI at baseline
and 2 years using a 3-tesla scanner (Magnetom Trio Tim,
Siemens, Germany). The protocol included high-resolution 3D
structural datasets, a diffusion tensor imaging sequence, a Pulsed
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Arterial Spin Labeling (PASL)-MRI perfusion sequence, a fluid
attenuated inversion recovery (FLAIR) image sequence, and a
functional sequence with an n-back working memory task.
Carotid ultrasonography
Bilateral carotid artery ultrasound imaging was performed at
baseline and 2 years according to a standardized protocol (Sala-
Vila et al., 2014). Main outcome measurements were mean and
maximum carotid IMT and plaque presence, maximum height
and area. Briefly, patients underwent sonographic assessment
with an Acuson X300 ultrasound system (Siemens, Germany)
equipped with a VF 10-5 linear multifrequency transducer
(frequency range 5–10 MHz) and ECG synchronization. The
same certified sonographer performed all examinations without
knowledge of group allocation. Secondary outcomes were mean
and maximum IMT at each carotid segment. IMT was defined
as the average of multiple distance readings between the
far wall lumen–intima and media-adventicia interfaces taken
bilaterally at common carotid artery 1 cm pre-bifurcation,
bifurcation, and internal carotid artery 1 cm after the flow
divider. Plaques were sought by using B-mode and color Doppler
examinations in both longitudinal and transverse planes to
take into consideration circumferential asymmetry and were
defined as a focal wall thickening encroaching into the arterial
lumen by at least 50% of the surrounding IMT value or with
thickness of at least 1.5 mm as measured from the media
adventitia interference to the intima-lumen surface. IMT and
plaque measurements were taken oﬄine by using edge-finding
software in the predefined segments of the arterial wall. Plaque
height was recorded at the more appropriate view, either
longitudinal or transversal. Plaque area was determined by the
technique of Spence et al. (2002). Plaque burden was recorded
for all study subjects and defined in two ways: the sum of
maximum heights of all plaques and the sum of areas of all
plaques.
The same certified sonographer blinded to treatment
allocation performed all scan readings. Consistency (reliability
or repeatability) of ultrasound carotid wall measurements was
evaluated by comparing results from repeated examinations in 14
subjects performed 3 days apart. Intraclass correlation coefficient
ranged from 0.92 to 0.96 for IMT mean (average of right and left)
and IMT maximum (maximum value from either right or left) in
common, bulb, and internal carotid segments.
DEXA studies
Total body lean and fat mass distribution and bone mineral
density were assessed by DEXA at baseline and 2 years. This is
a standard procedure performed using the whole-body scanner
GE Lunar iDXA (GE Healthcare, Madison, WI, USA) according
to the manufacturer’s specifications. The iDXA is a narrow fan-
beam DXA instrument with a high weight limit (204 kg) and a
relatively wide scanning space (66 cm) designed to accommodate
obese subjects. The subjects were positioned in the center of the
table for each scan. The appropriateness of patient’s position was
further assessed by the DXA software by means of an automatic
detection system. The instrument has three scan modes that
adjust the X-ray attenuation for the thickness of each patient.
For this study, scans were performed using the default scan
mode automatically selected by the DXA software. The GE Lunar
Body Composition Software was used to obtain fat-free mass
(FFM) and fat mass (FM) measurements, as well as segmental
FM and FFM distribution (trunk, right and left upper limb,
right and left lower limb, android, and gynoid) (Hull et al.,
2009).
Ambulatory blood pressure monitoring
Twenty-four-hour ambulatory blood pressure was monitored in
67% of participants selected at random at baseline and 2 years,
following the ESH/ESC recommendations (Mancia et al., 2013;
Doménech et al., 2014). The devices were Spacelabs 90207/90217
(Spacelabs R© Inc., Richmond, WA, USA), programmed for blood
pressure lectures every 20 min during the day and every 30 min at
night. Each participant kept a diary of daily activities and times of
going to bed and waking up. The report included the duration of
monitoring (h), the proportion of valid blood pressure registers,
and the mean values of systolic and diastolic blood pressure
during periods of activity, rest and the total recording period.
Telomere length
Leukocyte telomere length was determined in all participants
at baseline and in those undergoing sequential brain MRI at
the end of years 1 and 2. Fresh peripheral blood mononuclear
cells were separated from 5 mL of EDTA-collected blood by
Ficoll gradient centrifugation and also stored at −80◦C until
determination of telomere length by HTQFISH, which involves
in situ hybridization of telomere repeats to fluorescent primer
and analysis by fluorescence quantification of confocal images.
MicroRNA
Finally, at baseline and 1 year circulating miRNAs potentially
involved in lipoprotein metabolism will be screened by qRT-PCR
in plasma samples. The procedure requires a sample of ∼1 mL
plasma per measurement, kept in Trizol R© and stored at −80◦C
until the moment of the analysis.
Statistical Analyses
Sample size calculation was based on prior results from the
PREDIMED study (Valls-Pedret et al., 2015). We used as
reference the 2-year unadjusted changes in RAVLT (total
learning) scores in the Mediterranean diet enriched with nuts
compared to the control diet. In order to have a 90% power
to detect differences in the contrast with the null hypothesis,
assuming mean changes of 1.05 and 2.10 points in the control
and intervention groups, respectively, with a standard deviation
of 4.00, the total number of participants required was 308 per
group. Considering an estimated dropout rate of 10%, we needed
to include a total of 686 participants.
All data collected in the study were entered into an online
database (Onto CRF, Costaisa, Spain) managed for both centers.
An oversight committee blinded to subject allocation monitored
safety, quality of data collected, and trial’s progress.
Between-group differences in baseline neuropsychological and
ophthalmologic data will be examined by ANOVA and further
by ANCOVA adjusting for center, sex, age, education years,
APOE4 genotype, smoking, BMI, energy intake, physical activity,
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FIGURE 1 | Design of the Walnuts and Healthy Aging (WAHA) study.
diabetes, hyperlipidemia, and hypertension. Changes for each
individual cognitive test, cognitive composites, ophthalmologic
evaluations, and foods and nutrients ensuing intervention will
be assessed by ANOVA and further by ANCOVA adjusting for
the variables listed above. Statistical significance will be set at the
P < 0.05 level. Analyses will be performed using SPSS software,
version 16.0 (IBM Corp., New York, NY, USA).
STEPWISE PROCEDURES
As depicted in Figure 1, there are two main points of data
collection, at baseline and at the end of the study after
2 years of intervention. However, there are intermediate points
wherein relevant information is obtained. Thus, in mid-study
(12 months) a physical activity questionnaire was administered
and blood was collected for determination of safety biochemistry
analyses, lipid profile, and some secondary outcome variables
such as leukocyte telomere length. Nutritional information
and office blood pressure was obtained every 6 months, and
general health status, tolerance and side effects, medication
changes, and anthropometric data were ascertained every
2 months.
The pre-intervention visit with the study’s clinician lasted
1 h and consisted of a face-to-face interview with the candidate
wherein complete information on the trial was provided,
medical information was collected, inclusion/exclusion criteria
were recorded, office blood pressure was measured, an ECG
was performed, and the MMSE were administered. If the
candidate was suitable for the trial and willing to participate,
the informed consent was signed and blood extraction and urine
collection and the first neuropsychologist and ophthalmologic
visits were scheduled for next week. In the Barcelona site,
one part of the informed consent concerned brain MRI, and
candidates were asked to fill it in if willing to undergo the
procedure. Once the pre-established number of 30% of the
cohort was reached, no further candidates were offered brain
MRI.
The neuropsychologist visit included the comprehensive test
battery described in the Section “Cognitive Testing,” which took
90 min on average to complete. Whenever a cognitive alteration
was detected at this visit, the candidate was excluded from
further studies and was referred to the local Neurology clinic
with a report describing the test findings. In the Barcelona
site, the neuropsychologist provided full details on the brain
MRI examination to willing candidates and scheduled the
procedure.
In the ophthalmologic visit, which lasted approximately
30 min, a general history of eye health was taken and the
OCT was performed. Any candidate found to have advanced
AMD or bilateral cataracts precluding retinal examination was
excluded from the study and referred to the local Ophthalmology
clinic.
Once candidates were considered fit to enter the study after
assessment of the main outcomes, they were scheduled for the
first visit with the dietitian wherein they were randomized to
the walnut or control diets. Participants allocated to the walnut
diet received their first 2-month allotment of walnuts plus
extra packs for family needs. In the BCN site, after the first
dietitian visit all participants were scheduled for the secondary
outcome variables carotid ultrasound, DEXA for both body
composition and bone mineral density, and ambulatory blood
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FIGURE 2 | Recruitment and participant allocation.
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pressure monitoring. During the 2 years of the study, dietitians
took care of all aspects of follow-up at the bimonthly visits.
These included dietary compliance, tolerance and side-effects,
anthropometric measurements, delivery of walnuts and recount
of empty packages, and changes in clinical status and medication.
Clinical and medication changes were always reported to the
study’s clinician for confirmation and final recording in the online
study’s management system.
At the end of the study, all examinations related to primary
and secondary outcomes were repeated.
ANTICIPATED RESULTS
Data collection for the WAHA study was completed May 31,
2016. As shown in Figure 2, of the total 708 randomized subjects,
92% (n = 651) completed the first year of the study, while 89.8%
(n = 636) completed the 2 years. At the end of the study, the
dropout rate is 10.2%. Attrition rates were similar in the two
groups, n = 38 in the walnut group and n = 34 in the control
group.
The baseline characteristics of the study participants by group
are provided in Table 2. The mean age was 69.1 years and
67.9% were women. The characteristics of participants in the
two intervention groups were well balanced except for smoking
status, as there were more current smokers in the walnut group
than in the control group.
To objectively determine adherence to supplemental walnuts,
we measured the RBC proportions of ALA, a fatty acid
characteristic of walnuts, at baseline and after 1 year of
intervention in a random sub-sample of participants. There were
no significant differences in RBC ALA between intervention
TABLE 2 | Baseline characteristics of 708 WAHA participants by treatment
allocation.
Characteristics Walnut Control P-value∗
No. (%) 362 (51.1) 346 (48.9)
Enter with partner – no. (%) 98 (27.1) 88 (25.4) 0.62
Women – no. (%) 244 (67.4) 237 (68.5) 0.76
Age – year (mean ± SD) 69.4 ± 3.8 68.9 ± 3.5 0.07
Smoking – no. (%) 0.02
Never smoker 303 (83.7) 293 (84.7)
Former smoker 43 (11.9) 49 (14.2)
Current smoker 16 (4.4) 4 (1.2)
Education – no. (%) 0.83
Basic (0–4 years) 11 (3.0) 8 (2.3)
Elementary (5–8 years) 60 (16.6) 65 (18.8)
Secondary (9–12 years) 70 (19.3) 65 (18.8)
Post-secondary (>12 years) 221 (61.0) 208 (60.1)
Height – cm 164.3 ± 9.5 163.3 ± 9.0 0.14
Weight – kg 73.8± 15.2 73.5± 14.7 0.78
Body mass index – kg/m2 27.2 ± 4.3 27.5 ± 4.4 0.42
Hypertension – no. (%) 191 (52.8) 183 (52.9) 0.97
Type-2 diabetes – no. (%) 37 (10.2) 33 (9.5) 0.76
Dyslipidemia – no. (%) 203 (56.1) 182 (52.6) 0.35
Data are no. (%) or mean ± SD, as appropriate.
∗Obtained by Chi-square test or ANOVA, as appropriate.
groups at baseline (Figure 3A). After adjusting for center, age,
and sex, 1-year changes in RBC ALA were increases of 0.16%
of total fatty acids (95% confidence interval, 0.144–0.183) and
0.02% (95% confidence interval, 0.001–0.039) for the walnuts
and control group, respectively (P between groups < 0.001)
(Figure 3B).
FIGURE 3 | Baseline biomarkers of adherence to walnuts and change after 1 year by intervention group. RBC, red blood cells. In red, mean and 95% CI
(ANCOVA, adjusting for center, age, and sex). (A) Percentage of total fatty acids in RBC at baseline. Values are 0.233 (0.218–0.247) and 0.221 (0.206–0.236) for the
walnut and control groups, respectively. (B) Percentage of change of total fatty acids in RBC after 1 year. Values are 0.163 (0.144–0.183) and 0.019 (0.001–0.039)
for the walnut and control groups, respectively.
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POTENTIAL PITFALLS AND
COUNTERACTING MEASURES
The WAHA study was designed to assess whether a nutritional
intervention with walnuts for 2 years can prevent cognitive
impairment and preserve retinal health in a healthy elderly
population.
An unavoidable limitation of the study is not being able
to blind participants to the intervention since it consists of
a whole food. Another limitation is the difficulty in keeping
older, free-living volunteers in the study during 2 years and
ensuring compliance with the high-fat supplemental food in
the walnut diet group. The bimonthly visits by dietitians
and their availability to answer questions related to diet or
body weight and solve any problems with walnut ingestion
contributed to ensure participants’ loyalty. Thus, the final
dropout rate was only 10% and there was good compliance
with both eating the walnuts in the walnut group and not
eating them in the control group, as attested by 1-year changes
of RBC ALA, an objective biomarker of walnut consumption.
Finally, by the design of the recruitment methodology, self-
selected participants are in better health and have a higher
educational level than the general population, which could
lead to lower than expected age-related cognitive decline
and a lower probability of improving cognitive function
with the intervention. The mean baseline age of nearly
70 years, however, may partly overcome this healthy participant
effect.
The WAHA study has several strengths. This is the first
RCT that examines the effects of a single whole food, walnuts,
on cognitive performance and retinal health. By being an
RCT the results of the main outcomes should provide a
high level of evidence, while those of secondary outcomes,
such as brain MRI, carotid ultrasonography, 24-h ambulatory
blood pressure, inflammatory markers, and telomere length,
might shed light on the mechanisms of a putative beneficial
effect of the walnut diet on age-related disorders. Having
participants from two clinical centers located in different
geographical regions with variations in background diet and
lifestyle habits increases the external validity. We assessed the
primary outcome cognitive decline with a battery of standardized
neuropsychological tests designed to evaluate different cognitive
domains, making it a comprehensive approach. Changes in
the retina were also evaluated by a precise quantitative
technique such as OCT. Finally the free-living aspect of
the study makes it as close to real-life as possible since
there were no major diet changes to be made except to
either eat walnuts daily or abstain from eating walnuts.
The results should thus be applicable to a wider population
and might have a significant impact on global public health
recommendations.
In summary, the WAHA study evaluates cognitive function
and retinal health in an elderly cohort following daily ingestion of
walnuts for 2 years. The results might provide high-level evidence
of the benefit of regular walnut consumption on delaying the
onset of age-related degenerative diseases. The findings should
translate into public health policy and sound recommendations
to the general population.
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